FDA Panel To Review Atritech’s Watchman Stroke-Prevention Device
This article was originally published in The Gray Sheet
Executive Summary
FDA's Circulatory System Devices panel will meet April 23 to review a PMA for Atritech's Watchman minimally invasive stroke-prevention device for patients with atrial fibrillation, according to the company
You may also be interested in...
Panel Endorses Atritech Watchman Stroke-Prevention Device In Close Vote
An FDA advisory committee narrowly elected to recommend approval of Atritech's Watchman minimally invasive stroke-prevention device for atrial fibrillation patients, overcoming doubts about the size of the device's pivotal trial
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.